Corgenix Medical Corp is categorized under In Vitro Diagnostics in Broomfield, CO and active since 1990.
Corgenix Medical Corp was established in 1990, and today employs 1 to 4, earning Unknown per year. This is a In Vitro Diagnostics business, which does work in the B2B market, and is classified as a In Vitro Diagnostics, under code number 3391120 by the NAICS.
If you are seeking more information, feel free to contact Douglass Simpson, Chief Executive Officer at the company’s headquarters by writing to 11575 Main St Unit 400, Broomfield, Colorado CO 80020 or by phoning (303) 457-4345. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Corgenix Medical Corp |
| Contact Person: | Douglass Simpson, Chief Executive Officer |
| Address: | 11575 Main St Unit 400, Broomfield, Colorado 80020 |
| Phone Number: | (303) 457-4345 |
| Website Address: | corgenix.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 1990 |
| Location Type: | Headquarters |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | In Vitro Diagnostics |
| SIC Code: | 2835 |
| NAICS Code: | 3391120 |
| Share This Business: |
Corgenix Medical Corp was started in 1990 to provide professional In Vitro Diagnostics under the SIC code 2835 and NAICS code 3391120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Douglass Simpson, Chief Executive Officer for inquiries that concern Corgenix Medical Corp by calling the company number (303) 457-4345, as your correspondence is most welcome. Additionally, the physical location of the headquarters of Corgenix Medical Corp can be found at the coordinates 39.90637,-105.07185 as well as the street address 11575 Main St Unit 400 in Broomfield, Colorado 80020.
For its online presence, you may visit Corgenix Medical Corp’s website at corgenix.com and engage with its social media outlets through on Twitter and on Facebook.